Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Signs Bendamustine Deal With Symbio In Singapore And Korea, Highlighting Asian Oncology Market Potential

This article was originally published in PharmAsia News

Executive Summary

Tokyo-based biotech start-up Symbio will grant exclusive development and marketing rights for non-Hodgkin's lymphoma drug bendamustine to Japan's fourth-largest drug maker Eisai in both Korea and Singapore
Advertisement

Related Content

Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
Eisai To Reinforce Oncology R&D, Sales To Achieve 17% Income Rise
Daiichi Sankyo Reports First Annual Loss Since 2005 Merger; Plans To Improve Ranbaxy Management
Takeda Looks To Counter R&D Setbacks With Ramped Up Sales Efforts
Treanda Approved; Cephalon Ready With Tripled Salesforce To Launch In Chronic Lymphocytic Leukemia
Treanda Approved; Cephalon Ready With Tripled Salesforce To Launch In Chronic Lymphocytic Leukemia
Advertisement
UsernamePublicRestriction

Register

SC071753

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel